Full-Time

Senior Director or Vice President

Product

Formation Bio

Formation Bio

51-200 employees

AI-driven platform accelerates clinical-stage drug development

No salary listed

Boston, MA, USA + 1 more

More locations: New York, NY, USA

Hybrid

Hybrid work requires 3 days in office per week; reside in NYC metro or Boston metro or relocate.

Category
Product (1)
Required Skills
LLM
Data Science
Machine Learning
Data Governance

Get referred to Formation Bio

See people who can refer or advise you

Requirements
  • 10+ years of experience in tech delivery with progressively broader scope, including at least one role where you led product or technology strategy and were held accountable for business outcomes
  • Life sciences experience: You've built products in biotech, pharma, or a related industry. You understand the drug development lifecycle well enough to have informed opinions about where technology does and doesn't help. You've worked in an environment shaped by regulatory constraints and scientific uncertainty.
  • Strategic product thinker: You define product direction based on business outcomes, not feature velocity. You've owned a product area where success was measured in terms the business cared about - time saved, decisions improved, cost reduced - not just user engagement or ship rate.
  • AI fluency: You can evaluate AI/ML approaches, make build-vs-buy decisions on AI capabilities, and push your team to use AI where it creates real leverage. You've deployed or led the deployment of LLM-based or agentic systems in a professional context.
  • Technical fluency: You can engage deeply with engineers and data scientists on approach, architecture, and trade-offs. You can evaluate whether an ML model is solving the right problem, whether a data pipeline is reliable enough, and whether an engineering approach will scale.
  • Cross-functional leadership: You've led teams that included engineers, data scientists, and product managers. You know how to hire, develop, and hold people to high standards.
  • Business fluency: You can discuss clinical trial design, asset valuation, regulatory strategy, and competitive dynamics with senior leaders without retreating to technical jargon. You've been in rooms where the conversation was about business decisions, not product decisions, and you contributed.
  • Comfortable with ambiguity and autonomy: You are highly adaptable and curious. You've worked in early-stage companies, on transformation efforts or new initiatives where the scope was unclear and the playbook didn't exist. That energizes you rather than stalls you.
  • Mission-driven: You care about getting medicines to patients faster. That's what this company exists to do, and it matters to you.
Responsibilities
  • Own the product strategy for a defined problem domain (e.g., drug candidate evaluation, clinical trial execution, regulatory intelligence). Define what to build, what to deprioritize, and how to measure success.
  • Drive adoption of AI across your domain. We use LLMs, agentic workflows, and autonomous systems extensively. You should be pushing what's possible, not waiting for the technology teams to propose it.
  • Design systems that domain experts across the company can build on directly. Non-engineers are already creating their own technology - your solutions should accelerate that, not bottleneck it.
  • Lead a cross-functional team spanning engineering, data science, and product. Set the roadmap and make resourcing trade-offs based on business impact.
  • Work directly with our core functional teams as a strategic tech partner. Translate their problems into technology solutions - not by taking feature requests, but by understanding the domain well enough to see opportunities they may not.
  • Guide the data science and engineering approach within your domain, including real-world evidence analysis, prediction pipelines, clinical strategies, and dataset evaluation. You need enough technical judgment to know when an approach is sound and when to push back.
  • Maintain awareness of regulatory constraints. You don't need to be a regulatory expert, but you need to build products that work within GxP requirements and clinical data governance standards.

Formation Bio uses an AI-driven platform to speed up drug development by focusing on clinical-stage assets. It acquires and advances these assets using flexible financing structures, aiming to shorten timelines and cut costs for bringing new drugs to market. The core product is the proprietary AI tools that help with drug selection, development planning, and improving overall efficiency, enabling partnerships and successful commercialization with pharmaceutical and biotech companies. Compared with competitors, Formation Bio combines a data-powered approach with adaptable financing and asset acquisition strategies to move assets forward quickly and cost-effectively. The goal is to make treatments more accessible and affordable by accelerating development and enabling faster, more predictable commercialization through AI-enhanced decision making and flexible funding options.

Company Size

51-200

Company Stage

Series D

Total Funding

$530.3M

Headquarters

New York City, New York

Founded

2013

Get referred to Formation Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 2025 Series D raised $372 million, supporting pipeline expansion and platform buildout.
  • June 2026 BLKR201 entered Phase 1 five months after in-licensing, showing execution speed.
  • Formation Bio licensed IMIDomics anti-CD226 and Lynk BLKR201, broadening autoimmune assets.

What critics are saying

  • BLKR201 is first-in-human only; failure before early-2027 readout would damage platform claims.
  • Formation Bio depends on partners like Sanofi, Lynk, and IMIDomics for pipeline supply.
  • If gusacitinib or BLKR201 disappoint, the company becomes an expensive asset-flipping story.

What makes Formation Bio unique

  • Formation Bio pairs AI trial design with asset acquisitions and in-licensing.
  • Sanofi and OpenAI partnered with Formation Bio in June 2025 on AI drug development.
  • Michael Ehlers joined July 2026, adding Biogen and Pfizer R&D credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Jul 22nd, 2026
Formation Bio appoints Michael Ehlers as CSO to lead R&D strategy

Formation Bio has appointed Michael D. Ehlers as Chief Scientific Officer and Head of R&D. Ehlers will oversee portfolio strategy and advancement, from translational sciences through clinical development, and guide the scientific direction of Formation Bio's AI platform. Ehlers joins from MPM BioImpact, where he was an Entrepreneur Partner. He previously served as Executive Vice President of R&D at Biogen and held senior positions at Pfizer. Throughout his career, programmes under his leadership have produced six approved drugs spanning five indications and four drug modalities, with more than 40 programmes advanced into the clinic. Formation Bio is an AI-native pharma company that acquires clinical-stage assets and accelerates them through development using its proprietary AI platform.

PR Newswire
Jun 9th, 2025
Formation Bio Announces First Class Of Entrepreneurs In Residence To Drive Pipeline Growth And Strategic Partnerships

NEW YORK, June 9, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company focused on accelerating drug development, today announced the appointment of its first class of Entrepreneurs in Residence (EIRs): Kia Motesharei, Ph.D., Minji Kim Ph.D, MBA, John Taylor, M.S., and Anthony S. Walsh, D.Phil, These seasoned dealmakers will work closely with Chief Business Officer David Steinberg to expand the company's business development capabilities and further its mission to bring high-potential treatments to patients faster. Formation Bio acquires and in-licenses promising drug assets, advancing them through critical development milestones (Phase II and beyond), and then out-licensing for further advancement. The company's AI platform supports this lifecycle end-to-end—from asset identification and development strategy to execution of clinical trials aimed at greater speed and higher probability of success

Intelligence360 News
Jul 18th, 2024
Trialspark Dba Formation Bio Has Filed A Notice Of An Exempt Offering Of Securities To Raise $372,000,000.00 In New Equity Investment.

TrialSpark dba Formation Bio has filed a notice of an exempt offering of securities to raise $372,000,000.00 in New Equity Investment. TrialSpark dba Formation Bio has filed a notice of an exempt offering of securities to raise $372,000,000.00 in New Equity Investment.According to filings with the U.S. Securities and Exchange Commission, TrialSpark dba Formation Bio is raising up to $372,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Benjamine Liu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.About TrialSpark dba Formation BioFormation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program.To learn more about TrialSpark dba Formation Bio, visit http://www.formation.bio/TrialSpark dba Formation Bio Linkedin Page: https://www.linkedin.com/company/formationbio/Contact:Benjamine Liu, Chief Executive Officer866-283-7544https://www.linkedin.com/in/benjamine-liu-54306518/SOURCE: http://www.intelligence360.ioCopyright (c) 2024 SI360 Inc

FinSMEs
Jun 26th, 2024
Formation Bio Raises $372M in Series D Funding

Formation Bio, a NYC-based tech-driven and AI-native pharma company, raised $372M in Series D funding

HIT Consultant
May 21st, 2024
Sanofi, Formation Bio, Openai Partner On Ai-Powered Drug Discovery

What You Should Know:– Sanofi, a global pharmaceutical leader, Formation Bio, an AI-powered drug developer, and OpenAI, a leading research and development company in artificial intelligence, have announced a groundbreaking collaboration. The first-of-its-kind partnership in the pharma and life sciences industries aims to leverage AI to accelerate drug development and bring new medicines to patients faster.– Sanofi, Formation Bio, and OpenAI believe this collaboration will be a game-changer in the pharmaceutical industry. By combining their expertise in data, AI technology, and drug development, they aim to revolutionize the way new medicines are discovered and brought to market.A Symphony of ExpertiseThe collaboration will combine the unique strengths of each partner:Sanofi: Will contribute proprietary data for building custom AI models, furthering their goal of becoming the first biopharma company powered by AI at scale. This data will be crucial for training and refining the AI tools used in drug discovery.Will contribute proprietary data for building custom AI models, furthering their goal of becoming the first biopharma company powered by AI at scale. This data will be crucial for training and refining the AI tools used in drug discovery. OpenAI: World-renowned for its advancements in AI technology, OpenAI will contribute access to cutting-edge AI capabilities